ReviewTheScientificWorldJournal2015
Morphine for the treatment of pain in sickle cell disease.
Review in TheScientificWorldJournal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Arginine Therapy for Pain in Sickle Cell Disease: A Phase-2 Randomized, Placebo-Controlled Trial.American journal of hematology · 2025Trial
- Emergency care for children with sickle cell disease: a focus on pain and fever.Expert review of hematology · 2025Review
- Comparative Proteomic Analysis Reveals Altered Ciliary Proteins in Sickle Cell Disease.Journal of proteome research · 2025Article
- A Need for Daycare Unit for Sickle Cell Disease Patients in Oman.Sultan Qaboos University medical journal · 2024Article
- Opioid Use in Patients With Sickle Cell Disease During a Vaso-Occlusive Crisis: A Systematic Review.Cureus · 2022Review
- Pain in sickle cell disease: current and potential translational therapies.Translational research : the journal of laboratory and clinical medicine · 2021Review
- Heme Causes Pain in Sickle MiceAntioxidants & redox signaling · 2021Article
- Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease.Journal of clinical medicine · 2020Review
- Neuropathic Pain and Sickle Cell Disease: a Review of Pharmacologic Management.Current pain and headache reports · 2020Review
- Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence.Complementary therapies in medicine · 2020Review
- Changes in Blood Profile from Steady State in Patients with Sickle Cell Anemia Admitted for Vaso-occlusive Crisis and Acute Chest Syndrome.Advances in hematology · 2020Article
- Cross-cultural adaptation of the Pain Medication Questionnaire for use in Brazil.BMC medical research methodology · 2019Article
- Sensitization of nociceptors and dorsal horn neurons contributes to pain in sickle cell disease.Neuroscience letters · 2019Review
- Effect of chronic opioid therapy on pain and survival in a humanized mouse model of sickle cell disease.Blood advances · 2019Article
- Patient-reported experience measure in sickle cell disease.Archives of disease in childhood · 2018Article
- Targeting pain at its source in sickle cell disease.American journal of physiology. Regulatory, integrative and comparative physiology · 2018Review
- Endothelin type A receptors mediate pain in a mouse model of sickle cell disease.Haematologica · 2018Article
- Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic.Frontiers in psychiatry · 2018Review
- Targeting novel mechanisms of pain in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pain is a hallmark of sickle cell disease (SCD) and its treatment remains challenging. Opioids are the major family of analgesics that are commonly used for treating severe pain. However, these are not always effective and are associated with the liabilities of their own. The pharmacology and multiorgan side effects of opioids are rapidly emerging areas of investigation, but there remains a scarcity of clinical studies. Due to opioid-induced endothelial-, mast cell-, renal mesangial-, and epithelial-cell-specific effects and proinflammatory as well as growth influencing signaling, it is likely that when used for analgesia, opioids may have organ specific pathological effects. Experimental and clinical studies, even though extremely few, suggest that opioids may exacerbate existent organ damage and also stimulate pathologies of their own. Because of the recurrent and/or chronic use of large doses of opioids in SCD, it is critical to evaluate the role and contribution of opioids in many complications of SCD. The aim of this review is to initiate inquiry to develop strategies that may prevent the inadvertent effect of opioids on organ function in SCD, should it occur, without compromising analgesia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.